Navigation Links
Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting

* Preclinical study evaluating a clinically relevant model of normal human skin found that Menadione was the only agent capable of abrogating the cytotoxic effect of erlotinib * Phase I single agent Marqibo(r) showed OPTISOME(tm) agent was generally well tolerated in metastatic melanoma patients with an adverse event profile similar to conventional vincristine

SOUTH SAN FRANCISCO, Calif., June 4, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the presentation of data for Menadione and Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) at the 43rd Annual American Society of Clinical Oncology (ASCO) Annual Meeting.

"We are pleased to have the opportunity to share data regarding our emerging anti-cancer compounds at ASCO this year. Dr. Perez-Soler presented promising preclinical data showing that Menadione may be a useful topical agent in the treatment of the rash associated with EGFR inhibitors," stated Steven R. Deitcher, M.D., Hana Bioscience's Executive Vice President of Development and Chief Medical Officer. "Marqibo again showed that it is an active drug in another difficult-to-treat histology, namely metastatic melanoma. We are looking forward to further development of Menadione, Marqibo, and the other promising drug candidates in our pipeline."

Menadione is a topical agent being developed by Hana to treat skin rashes associated with use of Epidermal Growth Factor Receptor (EGFR) inhibitors. Skin toxicity is one of the most common side effects of EGFRs and is observed with the three approved agents of this class: cetuximab (Erbitux(r); Bristol-Myers Squibb/Imclone), panitumumab (Vectibix(r); Amgen), and erlotinib (Tarceva(r); Genentech/OSI). A preclinical study evaluating a clinically relevant model of normal human skin found that Menadione was the only agent capable of abrogating the cytotoxic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
2. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
3. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
(Date:12/22/2014)... Dec. 22, 2014 Apnea Sciences ( www.apneasciences.com ... in Aliso Viejo , California.  ... the tremendous growth and worldwide expansion, a new facility ... SnoreRx, the anti snore cure have exceeded our expectations ... "We are now in 23 countries and will be ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... Texas, Sept. 29 Luminex Corporation (Nasdaq: ... 2010 Prix Galien USA Award for its innovative xTAG® ... named Best Medical Technology at the Prix Galien USA ... 2010, at the American Museum of Natural History in ...
... asked today to make protecting the eyes from ... by increasing the prevalence of UV and eye-health ... as the Surgeon General, and in upcoming healthcare ... the Congressional Vision Caucus, provided the opening remarks ...
Cached Medicine Technology:Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 2Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority 3
(Date:12/24/2014)... New York, New York (PRWEB) December 24, 2014 ... lawsuits ( http://www.xareltolawsuit2015.com/ ) that allege the blood ... other complications has outlined a leadership structure for ... an Order dated December 17th, the Court plans ... for the parties and also plans on appointing ...
(Date:12/24/2014)... 2014 BambooIndustry.com a famous bamboo flooring ... Today, the company announces its multiple layer bamboo ... on these new products. , Bamboo panel is the ... multiple layer bamboo panel board features high quality selective ... emissions free. The bamboo panel consists of multiple layers ...
(Date:12/24/2014)... 2014 (HealthDay News) -- Adults who experienced childhood ... migraine headaches, suggests a study published online Dec. ... "Childhood maltreatment can have long-lasting effects, like associated ... study author Dawn Buse, director of behavioral medicine ... said in a journal news release. "When ...
(Date:12/24/2014)... CA (PRWEB) December 24, 2014 Gluten, ... havoc on those who have an intolerance to gluten, ... diarrhea, gas, bloating, migraine headaches, joint pain and fatigue. ... free diet plans that deliver safe and fast ... foods that trigger a gluten allergy reaction. These gluten ...
(Date:12/24/2014)... The report offers details on the global sports ... such as the key trends, the orthopedic market, the ... U.S. sports medicine, the impact of the global economy ... by the market. , Browse report with table of ... provides an overview of the global as well as ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2
... July 18 (HealthDay News) -- Correcting lazy eye in adults ... been able to do that -- at least partially and ... Someone with lazy eye -- ophthalmologists call it amblyopia -- ... other. Early treatment often has a child wearing a patch ...
... July 18 Two consumer,groups today filed an ... human embryonic stem cells held by the Wisconsin ... Foundation for Taxpayer and Consumer,Rights, and the Public ... of Appeals and Interferences. The PTO examiner narrowed,WARF,s ...
... in French . , Winnipeg (July ... Canadian Institutes of Health Research (CIHR) was announced today ... Secretary for Health, on behalf of Tony Clement, Minister ... investigating how to improve the application of mental health ...
... New research led by a Michigan State University scholar ... more emotionally unstable and harder to get along with ... employers are urged to guard against the use of ... firing. , Mark Roehling, associate professor of human resource ...
... national immunization awareness campaign to raise awareness, of ... ... CHEVY CHASE, Md., July 18 The COSHAR Foundation, a,nonprofit ... on minority and disadvantaged populations, hosts,National Women,s Health Awareness Day ...
... Blue Shield,United Concordia Companies, Inc. and Catholic Charities ... for Pittsburghers. Beginning at 10,a.m. and continuing until ... will,offer health information and dental screenings, restorations and ... long, oral health has received much less attention ...
Cached Medicine News:Health News:Magnetic Pulses to Brain Improve Lazy Eye in Adults 2Health News:Magnetic Pulses to Brain Improve Lazy Eye in Adults 3Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2Health News:Studies refute common stereotypes about obese workers 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 2Health News:The COSHAR Foundation Participates in Annual Women's Health Awareness Day 3Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2
... Compressor provides effective therapy at an affordable price. ... home or on the go and features ease ... reliable operation you have come to count on ... the perfect solution for those patients seeking a ...
... delivery is an important part of managing ... and convenient products mean delivering the aerosolized ... time while minimizing medication waste. Aerosol delivery ... line of Nebulizers, including the new NebuTech® ...
... SynergyPlus+ is recommended for people with low ... limbs associated with failed back syndrome, low ... people with post laminectomy pain, multiple back ... disease and Complex Regional Pain Syndrome (CRPS). ...
Whether you require high flow rates for critical situations or lower rates for others, this insufflator handles both situations equally well, regulated by the preselected pressure....
Medicine Products: